A case report of a dramatic response to Afatinib in a patient with advanced adenosquamous carcinoma lung cancer (ASC) harboring EGFR L861R

• DOI: 10.21203/rs.3.rs-1572588/v1
• Publication Date: 2022-04-22T17:22:30Z
• Authors: Tingting Zhao; Xianhua Gui; Shenyun Shi; Zhongyu Lu; Guanghua Lu; Wanglong Deng; Ran Ding; Fanfeng Bu; Jingjing Ding
• Keywords: Afatinib; Adenosquamous carcinoma

Abstract Lung cancer is a malignant tumor with high incidence and mortality in China. Furthermore, non-small cell lung cancer(NSCLC) accounts for more than 85%. About 30-40% of Asian populations carry epidermal growth factor receptor (EGFR) gene mutations. EGFR mutations mainly occur exon 18-21, the common are 19 deletions (19del), L858R, which all sensitive to tyrosine kinase inhibitors(EGFR-TKIs). Nevertheless, efficiency EGFR-TKIs on L861R remains unknown. In this article, we report patient adenosquamous carcinoma cancer(ASC) harboring who was treated afatinib obtained progression-free survival(PFS) 24 weeks.